Lilly To Present Final Overall Survival Analysis From The MONARCH 3 Study Of Verzenio And Additional Results From Its Breast Cancer Portfolio At The 2023 San Antonio Breast Cancer Symposium
Portfolio Pulse from Benzinga Newsdesk
Lilly will present the final overall survival analysis from the MONARCH 3 study of Verzenio at the 2023 San Antonio Breast Cancer Symposium. The study shows a numerical improvement in overall survival for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor, but the results were not statistically significant. Additional analyses of Verzenio and imlunestrant in combination with Verzenio will also be presented.
December 05, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lilly's presentation of the MONARCH 3 study results for Verzenio may not significantly impact the stock as the overall survival benefit was not statistically significant. However, the additional data on Verzenio and imlunestrant could be of interest to investors.
While the numerical improvement in overall survival is a positive development, the lack of statistical significance may temper investor reactions. The stock impact is likely to be neutral in the short term as the market digests the full implications of the data and awaits further results from additional analyses.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 80